BURLINGTON, MA – Rhythmia Medical Inc., highlights the publication of results from a feasibility study of the Rhythmia Mapping System in Circulation Arrhythmia and Electrophysiology.
The article, “Rapid, High-Resolution Electroanatomical Mapping: Evaluation of a New System in a Canine Atrial Linear Lesion Model”, was authored by Drs. Warren Jackman, Hiroshi Nakagawa and their colleagues at the Heart Rhythm Institute at Oklahoma University. The article highlights the advanced capabilities of the system to “accurately and quickly identify geometry and complex patterns of activation in the canine right atrium with little or no manual annotation of activation time”.
“We are very pleased with the results of this evaluation and other studies that demonstrate the advances of our Electrophysiology 3D Mapping and Navigation System” noted Doron Harlev, Co-Chief Executive Officer of Rhythmia Medical, Inc. “We look forward to continuing to advance our development, clinical and regulatory efforts with this very promising technology platform.”
The article can be accessed through: http://www.ncbi.nlm.nih.gov/pubmed/22392447
Cardiac arrhythmia affects more than 7.5 million people in the United States and Europe, and is a life-threatening condition that can lead to stroke or heart failure. Catheter ablation procedures, currently performed at a rate of over 500,000 per year, represent a greater than $2 billion market with one of the fastest growth rates in medical devices.
About Rhythmia Medical
Founded in 2004, Rhythmia Medical, Inc. is developing a next generation Mapping, Visualization and Navigation system for the treatment of cardiac arrhythmias. The company is conducting human clinical testing outside the US and is working with several of the leading clinicians in this field around the world. The Burlington, Massachusetts based company has raised financing from a number of investors, including corporate, private and leading medical device venture capital firm Norwich Ventures. The Company has been awarded ISO 13485 certification. Additional information can be found at www.rhythmia.com.